Cancer Stem Cell News Volume 4.45 | Dec 2 2015

PAR1 Inhibition Suppresses the Self-Renewal and Growth of A2B5-Defined Glioma Progenitor Cells and Their Derived Gliomas In Vivo
Lentiviral knockdown of PAR1 inhibited the expansion and self-renewal of human glioblastoma-derived A2B5⁺ tumor-initiating progenitor cells (TPCs) in vitro, while pharmacological inhibition of PAR 1 similarly slowed both the growth and migration of A2B5⁺ TPCs in culture. [Oncogene] Abstract

Downregulation of COMMD1 by miR-205 Promotes a Positive Feedback Loop for Amplifying Inflammatory- and Stemness-Associated Properties of Cancer Cells
Analysis of microarray data revealed upregulation of nuclear factor-κB–regulated pro-inflammatory genes and downregulation of copper metabolism MURR1 domain-containing 1 (COMMD1) during the enrichment for stemness in SAS head and neck squamous-cell carcinoma cells. [Cell Death Differ] Full Article

Non-Epigenetic Function of HDAC8 in Regulating Breast Cancer Stem Cells by Maintaining Notch1 Protein Stability
The authors report a novel non-epigenetic function of histone deacetylase (HDAC) 8 in activating cancer stem cell-like properties in breast cancer cells by enhancing the stability of Notch1 protein. [Oncotarget] Full Article

CD44 Is Functionally Crucial for Driving Lung Cancer Stem Cells Metastasis through Wnt/β-Catenin-FoxM1-Twist Signaling
Investigators found that CD133⁺CD44⁺ cells which were derived from primary lung adenocarcinoma possessed cancer stem cell-like features. Furthermore, CD44 was demonstrated functionally crucial to drive metastatic potential of CD133⁺CD44⁺ lung cancer stem cell-like cells by in vitro and in vivo experiments. [Mol Carcinog] Abstract

Phenotype Plasticity Rather than Repopulation from CD90/CK14+ Cancer Stem Cells Leads to Cisplatin Resistance of Urothelial Carcinoma Cell Lines
Based on the fact that urothelial carcinoma is postulated to constitute cancer stem cells and the origin of cisplatin resistance, researchers enriched urothelial carcinoma cell lines for CD90 and studied the tumor-initiating potential of these separated cells in vitro. [J Exp Clin Cancer Res] Full Article

The Novel Oral TGF-β Signaling Inhibitor EW-7197 Eradicates Chronic Myelogenous Leukemia-Initiating Cells
Scientists investigated the therapeutic potential of EW-7197, an orally bioavailable TGF-β signaling inhibitor, to suppress chronic myelogenous leukemia leukemia-initiating cells in vivo. [Cancer Sci] Abstract

Lgr5 Methylation in Cancer Stem Cell Differentiation and Prognosis-Prediction in Colorectal Cancer
Researchers investigated the methylation status within the leucine-rich-repeat-containing G-protein-coupled receptor 5 (lgr5) promoter and evaluated its relationship with cancer stem cell differentiation, prognosis for colorectal cancer, and its clinicopathological features. [PLoS One] Full Article

Visit our reviews page to see a complete list of reviews in the Cancer Stem Cell research field.

NCCN Collaborates with Bristol-Myers Squibb to Study PD-L1 Expression and Test Interpretation in Lung Cancer
To improve the scientific knowledge concerning PD-L1 protein expression and help pathologists understand the diagnostic nuances associated with lung cancer treatment, the National Comprehensive Cancer Network^® (NCCN^®) Oncology Research Program and Bristol-Myers Squibb (BMS) are collaborating on the NCCN/BMS Thoracic Pathology Protocol Development Team. [National Comprehensive Cancer Network^®] Press Release

From our sponsor: Learn about detecting cancer stem cells with ALDEFLUOR™. Watch the webinar.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the Cancer Stem Cell community.

NEW Director – Cancer Institute (North Shore-LIJ Health System)

NEW Postdoctoral Fellow – Systems Biology of Cancer Metabolism (Technion – Israel Institute of Technology)

NEW Postdoctoral Fellow – Epigenetics and Cancer (Moffitt Cancer Center)

Assistant Member – Radioimmunotherapy (Fred Hutchinson Cancer Research Center)

Investigator – Cancer Biology (Wake Forest Baptist School of Medicine)

Postdoctoral Research Fellow – Stem Cell Research (The University of Texas Medical School At Houston)

Faculty Positions – Cancer Pharmacology (Northwestern University)

Group Leader Position – Cancer Research (Oslo University Hospital)

Research Technician II – Stem Cell and Gene Therapy (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.